Parkinson's
64 programs · 63 companies
Programs
64
Companies
63
Trials
59
MOAs
38
HPK1iKRASG12CiCDK4/6iFXIaiBCL-2iSGLT2iALKiPD-L1iAnti-TauSTINGag
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-6974 | Preclinical | CD19 | ||
| AZN-8478 | NDA/BLA | SHP2 | ||
| Ivocapivasertib | Phase 1 | BET | ||
| NVO-7877 | Preclinical | GPRC5D | ||
| Tezecilimab | NDA/BLA | Tau | ||
| BAY-3308 | Phase 1 | ALK | ||
| Zanuratamab | Phase 1/2 | CDK2 | ||
| BNT-8090 | Phase 2 | AuroraA | ||
| Adagracapivasertib | NDA/BLA | BET | ||
| BGN-3305 | Phase 2 | BCMA | ||
| Miritinib | Phase 3 | TIGIT | ||
| Fixatuximab | Preclinical | CFTR | ||
| Tirarapivir | Approved | SGLT2 | ||
| NUV-283 | Phase 3 | B7-H3 | ||
| FHT-3384 | NDA/BLA | JAK2 | ||
| CVA-2171 | Phase 1/2 | LAG-3 | ||
| BVN-7642 | Phase 2 | CFTR | ||
| CSL-4826 | NDA/BLA | WRN | ||
| Elraderotide | Phase 1/2 | Tau | ||
| Voxarapivir | Phase 2 | GPRC5D | ||
| Teratinib | Phase 2/3 | IL-23 | ||
| HOV-IIT-903 | Phase 1/2 | PD-1 | ||
| Sovanesiran | Phase 1 | CFTR | ||
| Nidavorutinib | NDA/BLA | KRASG12C | ||
| SAV-5205 | NDA/BLA | BTK | ||
| Talavorutinib | Phase 1 | C5 | ||
| GOS-5370 | Phase 2/3 | TNFα | ||
| Tixafutibatinib | Phase 1/2 | USP1 | ||
| Niraderotide | Phase 2/3 | CDK2 | ||
| COR-8406 | Phase 2 | ALK | ||
| Tixanaritide | Phase 2/3 | AuroraA | ||
| Tirainavolisib | Phase 3 | FLT3 | ||
| Zorifotisoran | Preclinical | IL-23 | ||
| LTR-8109 | Phase 1 | SHP2 | ||
| Datorasimod | Approved | C5 | ||
| Adagraosocimab | Preclinical | DLL3 | ||
| Capisotorasib | Phase 1 | CD3 | ||
| IMM-5415 | Preclinical | PD-1 | ||
| Adagrazasiran | Phase 3 | FLT3 | ||
| INB-9118 | Phase 3 | Aβ | ||
| Miricapivasertib | Phase 3 | PRMT5 | ||
| Pexafotisoran | Phase 1/2 | GIP-R | ||
| Niracagene | Preclinical | BCL-2 | ||
| 212-6798 | Phase 1/2 | CD19 | ||
| Zorisertib | Approved | SHP2 | ||
| Doxatenlimab | Phase 3 | MALT1 | ||
| MIR-4070 | Phase 1/2 | USP1 | ||
| AVA-8598 | Phase 2/3 | CD38 | ||
| Darafutibatinib | NDA/BLA | GPRC5D | ||
| Voxarapivir | NDA/BLA | B7-H3 | ||
| IMV-3202 | Approved | Tau | ||
| Tixatinib | Phase 2 | WEE1 | ||
| MRE-2348 | Preclinical | FXIa | ||
| IMT-6167 | Phase 1 | CD20 | ||
| Rilutapinarof | Phase 1 | MET | ||
| Semazanubrutinib | Phase 3 | TROP-2 | ||
| Rimabrutinib | Approved | WRN | ||
| RIK-IIT-592 | Phase 1/2 | MDM2 | ||
| 600-5291 | Phase 2 | LAG-3 | ||
| Tixasotorasib | Preclinical | PSMA | ||
| Talatuximab | Phase 2 | AuroraA | ||
| GR-6650 | NDA/BLA | PLK4 | ||
| Polafotisoran | NDA/BLA | TNFα | ||
| 453-4569 | Phase 2/3 | MET |
Trials (59)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT08462786 | NVS-6974 | Preclinical | Completed |
| NCT08542868 | Ivocapivasertib | Phase 1 | Active |
| NCT03094542 | Ivocapivasertib | Phase 1 | Completed |
| NCT05228209 | BNT-8090 | Phase 2 | Terminated |
| NCT07254830 | Adagracapivasertib | NDA/BLA | Recruiting |
| NCT06253313 | BGN-3305 | Phase 2 | Completed |
| NCT07774206 | Fixatuximab | Preclinical | Terminated |
| NCT03528796 | Tirarapivir | Approved | Terminated |
| NCT03837934 | Tirarapivir | Approved | Active |
| NCT03830158 | Tirarapivir | Approved | Recruiting |
| NCT08282505 | NUV-283 | Phase 3 | Terminated |
| NCT05471654 | NUV-283 | Phase 3 | Terminated |
| NCT07492847 | NUV-283 | Phase 3 | Recruiting |
| NCT07530717 | NUV-283 | Phase 3 | Recruiting |
| NCT03118813 | CVA-2171 | Phase 1/2 | Completed |
| NCT08923706 | Teratinib | Phase 2/3 | Active |
| NCT08982351 | HOV-IIT-903 | Phase 1/2 | Terminated |
| NCT03637239 | SAV-5205 | NDA/BLA | Not yet recr... |
| NCT08299222 | Talavorutinib | Phase 1 | Completed |
| NCT07928113 | Talavorutinib | Phase 1 | Not yet recr... |